Testing imaging and biopsy options for people with BAP1 risk
Part of Cancer clinical trials.
This study looks at how well advanced scans, liquid biopsy tests, and small follow-up procedures can find early mesothelioma in people with a high-risk BAP1 gene condition. It may help catch cancer earlier when treatment could work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 30 or older
- You have a known or suspected inherited BAP1 gene risk (BAP1 tumor predisposition) OR are a close family member (parent/sibling/child/grandparent/niece/nephew) of someone with a confirmed BAP1 condition
- Understand the study and agree to sign a consent form
- Have finished the study’s earlier genetic testing step showing a BAP1 (or other related inherited) mutation
- Have already joined the related parent study (protocol 06C0014) for thoracic cancer risk testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with a harmful (deleterious) BAP1 gene change to learn how it affects health over time. It may help researchers better understand mesothelioma risk and the long-term outcomes for families with this genetic mutation.
This study tests an oral medication called decitabine/cedazuridine (INQOVI) that may help delay or prevent progression in people with early-stage mesothelioma who carry a BAP1 mutation. The treatment is given as a pill and aims to reactivate genes that may help control cancer growth.
This study collects tissue samples (biopsies) and health information to better understand malignant mesothelioma and certain related solid tumors that may produce a protein called mesothelin. It may help future research and treatments, and you can only join if your diagnosis is confirmed and it’s safe for you to have the tissue taken.
This study looks at how the BAP1 gene affects cancer risk and what cancers people develop, including within families. You may be able to join if you have a known BAP1-related mutation, a strong family cancer history, or a concerning cancer pattern linked to BAP1.
This trial tests a new drug called BMS-986504 in people whose mesothelioma has come back after treatment and whose tumors lack a protein called MTAP. The drug may help by blocking a specific pathway that these cancer cells need to grow.
This trial tests ways to screen people who have a family-passed (inherited) gene mutation linked to higher pancreatic cancer risk. The goal is to find pancreatic cancer earlier and improve how screening is done for people at increased risk.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.